Drugs which are already (U.S.) Food and Drug Administration (FDA) approved could be effective in treating of lung cancer in “never-smokers,” researchers reported on Sept. 30, 2021 in… read more.
BeiGene has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib)… read more.
In fruit flies, antioxidants reverse tumor-related cardiac dysfunction. Ohio State University A new study in animal models shows that the presence of a cancer tumor alone can lead… read more.
BUFFALO, N.Y. — Having second- or third-degree relatives with colorectal cancer increases a person’s risk of developing the disease, according to the findings of a study led by… read more.
Massachusetts Institute of Technology MIT engineers, in collaboration with scientists at Cancer Research UK Manchester Institute, have developed a new way to grow tiny replicas of the pancreas,… read more.
The NHS will launch the world’s largest trial of a revolutionary new blood test that can detect more than 50 types of cancer before symptoms appear. The first… read more.
MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS… read more.
In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Targeting these T cells, which are… read more.
Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukaemia (CLL) make it more challenging for chimeric antigen… read more.
Genentech/Roche announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based… read more.
In 2011, Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, received accelerated approval by the FDA for Istoda (romidepsin), a histone deacetylase (HDAC) inhibitor, as… read more.
BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that Brukinsa (zanubrutinib) has… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
